A new cost-saving in vivo shuttle session on validated syngeneic mouse tumor models
09 / 08 / 2020
How about an opportunity to assess your compounds in a comprehensive and cost-effective manner?
09 2020
Scientific communications
07 2020
M2 macrophage polarization assay for in vitro assessment of drug ability to relieve immunosuppressive features
07 / 22 / 2020
Macrophages - one of the most abundant antigen-presenting cells - represent by themselves a wide group of functionally-different subpopulations involved in several immunological functions, including inflammatory responses and tissue homeostasis maintain & repair.
07 2020
A syngeneic orthotopic EMT6 breast mouse model for preclinical immuno-oncology testing of novel anti-cancer strategies
07 / 09 / 2020
Because of metastatic development of the disease, among other characteristics, and regardless of survival data, breast cancer was shown to be particularly difficult to treat. However, metastases as well as resistance to therapies continue to be a great challenge and the development of new therapeutic strategies is increasingly necessary.
04 2020
Cytokine release as a relevant surrogate for the immune cell subset function assessment on an in vitro platform of IO
04 / 16 / 2020
Explicyte’s expertise and advanced technologies have been harnessed so as to build a cell-based service platform for immuno-oncology (IO) assessment and drug discovery.
03 2020
IDO Targeting in Sarcoma: Biological and Clinical Implications
03 / 05 / 2020
New explicyte publication in frontiers in Immunology!
02 2020
B cells as key player in shaping anti-tumor immune response
02 / 20 / 2020
B cells to the forefront of cancer immunotherapy
01 2020
Featured model - Orthotopic glioblastoma mouse model
01 / 07 / 2020
Our syngeneic glioma mouse model, based on the intracranial inoculation of Luc2-expressing GL261 cells and bioluminescence imaging for tumor growth monitoring, represents a suitable tool for chemo- and immunotherapy assessment. It closely mimics the human disease in terms of tumor progression and anti-tumor response, and recapitulates glioblastoma characteristic features including among others tumor immune cell infiltration and tumor-induced immunosuppression.
Model responsiveness to standard Temozolomide and immune checkpoint inhibitors i.e. anti-CTLA4, anti-PD1, and anti-PDL1 antibodies, makes it well-suited for testing candidate compounds for their efficacy, as single agents and/or in combination, in promoting anti-tumor activity.
12 2019
Explicyte poster at ESMO IO Congress 2019
12 / 17 / 2019
"Comprehensive assessment of anti-tumor PDL1 blockade effect in a sarcoma mouse model"
11 2019
Antibody-dependent cell-mediated cytotoxicity (ADCC) assay for in vitro testing
11 / 21 / 2019
See our case study below or download our white paper!
Many cells of the innate immunity work in concert with the adaptive immune system to effectively afford protection.
10 2019
In vivo syngeneic tumor models for novel drug assessment and MoA deciphering in a cost-saving way
10 / 09 / 2019
How about an opportunity to assess your compounds in a comprehensive and cost-effective manner?